A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, Intermediate Risk Early Breast Cancer

Trial Profile

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, Intermediate Risk Early Breast Cancer

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs Ribociclib (Primary)
  • Indications Adenocarcinoma; Breast cancer
  • Focus Therapeutic Use
  • Acronyms EarLEE-2
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 14 Nov 2017 According to a Novartis media release, data from this trial will be presented at the upcoming 40th annual San Antonio Breast Cancer Symposium (SABCS).
    • 02 Oct 2017 Planned End Date changed from 22 Sep 2025 to 17 Nov 2025.
    • 02 Oct 2017 Planned primary completion date changed from 22 Sep 2025 to 17 Nov 2025.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top